<DOC>
	<DOCNO>NCT02156570</DOCNO>
	<brief_summary>The purpose study examine whether patient acute early chronic hepatitis C virus ( HCV ) infection treat effectively safely interferon-sparing regimen combine new direct acting antiviral drug ( sofosbuvir ) one standard treatments chronic hepatitis C ( ribavirin ) . In particular , study investigate whether treatment acute early chronic HCV shorten . The study ass efficacy look proportion people clear virus ( virus detectable blood ) end treatment , 1 , 3 6 month treatment . The hypothesis short course ( 6 week ) dual therapy use sofosbuvir RBV result successful virological eradication majority ( ≥80 % ) subject treat recently acquire HCV .</brief_summary>
	<brief_title>DAA-based Therapy Recently Acquired Hepatitis C II ( DAA = Directly Acting Antiviral )</brief_title>
	<detailed_description>To evaluate efficacy , safety acceptability interferon-sparing strategy sofosbuvir ribavirin treatment recently acquire HCV infection . An open label single arm multicentre study Treatment participant : Sofosbuvir 400mg daily weight base ribavirin ( 1000mg &lt; 75 kg , 1200mg &gt; /= 75kg ) Duration treatment 6 week subject follow 52 week observational follow-up Total study duration = 58 week Primary endpoint : SVR 12</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Provision write informed consent Male female patient age 18 year Willing use two effective method contraception treatment period 24 week post . HBsAg negative Detectable HCV RNA screening ( &gt; 10,000 IU/ml ) , opinion investigator unlikely demonstrate spontaneous viral clearance Compensated liver disease ( ChildPugh A ) Negative pregnancy test screen 24 hour prior first dose study drug Medically stable basis physical examination , medical history vital sign Adequate English provide reliable response study questionnaires Recent hepatitis C infection , define : A ) ) First antiHCV Ab HCV RNA positive within previous 6 month ii ) Documented antiHCV Ab negative within 24 month prior antiHCV antibody positive result , OR B ) ) First antiHCV Ab HCV RNA positive within previous 6 month ii ) acute clinical hepatitis ( jaundice ALT &gt; 10 X ULN ) within previous 12 month prior first positive HCV antibody HCV RNA , cause acute hepatitis identifiable If coinfection HIV document , subject must meet following criterion : Antiretroviral ( ARV ) untreated &gt; 8 week precede screen visit CD4 T cell count &gt; 500 cells/mm3 OR On stable ARV regimen &gt; 8 week prior screen visit , CD4 T cell count &gt; 200 cells/mm3 undetectable plasma HIV RNA level . Standard exclusion RBV therapy Pregnancy/lactation male subject whose female partner pregnant Subject history decompensated liver disease : history ascites , hepatic encephalopathy , bleed oesophageal varix , and/or follow screen laboratory result : a.INR ≥1.5 ; Serum albumin &lt; 3.3 g/dL ; Serum total bilirubin &gt; 1.8 time upper limit normal , unless isolated subject Gilbert 's syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Acute/early chronic</keyword>
	<keyword>Recently acquire</keyword>
	<keyword>Directly act antiviral therapy</keyword>
	<keyword>Sofosbuvir</keyword>
	<keyword>Ribavirin</keyword>
</DOC>